Improvement in lipid profile of the patients with saxagliptin as add on therapy in patients of uncontrolled type 2 DM who were on metformin alone

---

Original Article

Author Details : Akshay C. Dahiwele, Dinesh Kansal, Dheeraj Kapoor, Praveen Sharma

Volume : 2, Issue : 4, Year : 2017

Article Page : 115-117

Suggest article by email

Get Permission

---

Abstract

Introduction: Diabetes is characterized by chronic hyperglycemia and deranged carbohydrate, lipid and protein metabolism. This study shows an improvement in lipid profile (TC, TG, LDL and HDL) with saxagliptin in patients of uncontrolled type 2 diabetes mellitus (T2DM) who were previously on metformin monotherapy.
Materials and Method: A total of 30 patients with uncontrolled diabetes were enrolled, who were on metformin 1500 mg daily. Patients were given metformin 500 mg twice a day and saxagliptin 2.5 mg once a day. Patients were followed up at 1^st, 3^rd and 6^th month and lipid profile (TC, TG, LDL and HDL) was estimated.
Results: The mean age ± SD in males and females was 61.42yrs ± 6.99 and 55.93yrs ± 5.74 respectively. The mean change in value from baseline at 24 weeks was TC= 9.66%, TG= 9.40%, LDL= 14.87%, HDL= 5.63%. A highly significant difference was seen at 0 v/s 1, 0 v/s3 and 0 v/s 6 months in lipid profile values.
Conclusion: Saxagliptin has shown an improvement in lipid profile (TC, TG, LDL, HDL) during 6 months of treatment duration in patients of T2DM.

Keywords: Saxagliptin, Uncontrolled Type 2DM, Metformin, Lipid Profile

 

How to cite : Dahiwele A C, Kansal D, Kapoor D, Sharma P, Improvement in lipid profile of the patients with saxagliptin as add on therapy in patients of uncontrolled type 2 DM who were on metformin alone. Indian J Clin Anat Physiol 2017;2(4):115-117

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.